To include your compound in the COVID-19 Resource Center, submit it here.

Global Blood adds $216M in latest follow-on

Sickle cell company Global Blood Therapeutics Inc. (NASDAQ:GBT) raised $216 million through the sale of

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE